Success Metrics

Clinical Success Rate
54.5%

Based on 6 completed trials

Completion Rate
55%(6/11)
Active Trials
0(0%)
Results Posted
117%(7 trials)
Terminated
5(42%)

Phase Distribution

Ph phase_3
4
33%
Ph phase_2
7
58%
Ph not_applicable
1
8%

Phase Distribution

0

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
7(58.3%)
Phase 3Large-scale testing
4(33.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(6)
Terminated(5)
Other(1)

Detailed Status

Completed6
Terminated5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
54.5%
Most Advanced
Phase 3

Trials by Phase

Phase 27 (58.3%)
Phase 34 (33.3%)
N/A1 (8.3%)

Trials by Status

unknown18%
completed650%
terminated542%

Recent Activity

0 active trials
Showing 5 of 12
unknownphase_3

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

NCT01827605
completedphase_2

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

NCT00290511
terminatedphase_3

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

NCT00322218
terminatedphase_3

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

NCT01510184
terminatedphase_3

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT01827605Phase 3

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Unknown
NCT00290511Phase 2

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

Completed
NCT00322218Phase 3

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Terminated
NCT01510184Phase 3

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Terminated
NCT01662102Phase 3

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Terminated
NCT00591630Phase 2

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Completed
NCT00119730Phase 2

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

Completed
NCT00387023Not Applicable

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

Completed
NCT00493454Phase 2

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Terminated
NCT00521560Phase 2

A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas

Completed
NCT00354822Phase 2

Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.

Terminated
NCT00850512Phase 2

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12